Organisation paid for research Program year 2025 Source: CMS Open Payments

Vivent Health

Neither a doctor nor a teaching hospital

Research payments

$347,680

30 payments

Through program year 2025, Vivent Health is reported as receiving $347,680 in research payments, across 30 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $90,000 2
2024 Research $35,477 4
2023 Research $119,594 8
2022 Research $96,750 11
2021 Research $5,859 5

Breakdown

Who paid Research payments · program years 2021–2025
  1. Gilead Sciences, Inc. $308,359 11 payments
  2. ViiV Healthcare Company $34,199 18 payments
  3. Merck Sharp & Dohme Corporation $5,121 1 payment
Studies the money was for Research payments · program years 2021–2025
  1. The implementation and up-take of rapid start/same-day PrEP services in Black and LatinX MSM $77,000 1 payment
  2. The implementation and up-take of rapid start/same-day PrEP services in Black and LatinX MSM $60,000 1 payment
  3. The implementation and up-take of rapid start/same-day PrEP services in Black and LatinX MSM $54,200 1 payment
  4. The implementation and up-take of rapid start/same-day PrEP services in Black and LatinX MSM $54,200 1 payment
  5. The implementation and up-take of rapid start/same-day PrEP services in Black and LatinX MSM $30,000 1 payment
  6. The implementation and up-take of rapid start/same-day PrEP services in Black and LatinX MSM $27,100 1 payment
  7. A Phase Iib, Randomized, Double-Blind, Parallel-Group Study to Assess $25,194 15 payments
  8. Paired Patient Reported Exp and Benefit of Treatment W Dovato $8,250 2 payments
  9. A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine,Islatravir DOR,ISL 100 mg,0.25 mg Once-Daily in HIV-1 Infected Treatment-Na ve Participants $5,121 1 payment
  10. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults $2,101 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record